Related Experiment Video
Updated: Jul 8, 2025

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Lrp10 suppresses IL7R limiting CD8 T cell homeostatic expansion and anti-tumor immunity
Abstract:
Signals emanating from the T cell receptor (TCR), co-stimulatory receptors, and cytokine receptors each influence CD8 T cell fate. Understanding how these signals respond to homeostatic and microenvironmental cues can reveal new ways to therapeutically direct T cell function. Through forward genetic screening in mice, we discovered that loss-of-function mutations in LDL receptor related protein 10 ( Lrp10 ) caused naïve and central memory CD8 T cells to accumulate in peripheral lymphoid organs. Lrp10 encodes a conserved cell surface protein of unknown immunological function. Lrp10 was induced with T cell activation and its expression post-translationally suppressed IL7 receptor (IL7R) levels. Accordingly, Lrp10 deletion enhanced T cell homeostatic expansion through IL7R signaling. Lrp10 -deficient mice were also intrinsically resistant to syngeneic tumors. This phenotype depended on dense tumor infiltration of CD8 T cells that displayed increased memory cell characteristics, reduced terminal exhaustion, and augmented responses to immune checkpoint inhibition. Here, we present Lrp10 as a new negative regulator of CD8 T cell homeostasis and a host factor that controls tumor resistance with implications for immunotherapy.
Insights
Loss of LDL receptor related protein 10 (Lrp10) enhances CD8 T cell accumulation and anti-tumor immunity. This discovery offers new therapeutic strategies for directing T cell function and improving cancer immunotherapy.
Area of Science:
- Immunology
- Cell Biology
- Genetics
Background:
- CD8 T cell fate is dictated by signals from T cell receptor, co-stimulatory, and cytokine receptors.
- Understanding T cell responses to homeostatic and microenvironmental cues is crucial for therapeutic interventions.
Conclusions:
- Lrp10 acts as a novel negative regulator of CD8 T cell homeostasis.
- Lrp10 deficiency promotes anti-tumor immunity by enhancing CD8 T cell function and response to immunotherapy.
- Targeting Lrp10 presents a potential therapeutic strategy for cancer immunotherapy.
More Related Videos
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Abnormal Proliferation
lncRNA - Long Non-coding RNAs
Experimental RNAi

